Abstract
Background
We aimed to develop a clinicopathological model that would predict the risk of bone metastasis (BM) in hepatocellular carcinoma (HCC).
Methods
We first evaluated a training cohort of 201 HCC patients who had undergone hepatectomy and found that the following factors independently predicted BM development: vascular invasion, tumor-node-metastasis stage, CXCR4, connective tissue growth factor, and interleukin-11. These variables were used to construct a clinicopathological prediction model that may be scored from 0 to 19. The predictive value of the model was demonstrated in a validation cohort of 179 post-hepatectomy HCC patients.
Results
During a median follow-up of 54.3 months for the training cohort and 52.5 months for the validation cohort, 23 patients (11.4%) in the former and 19 patients (10.6%) in the latter developed BM. A cutoff value of 9.4 best discriminated BM risk and was able to exclude future BM development with high accuracy in the validation cohort. The sensitivity and specificity of the method were 73.7 and 78.7%, respectively, the positive predictive value was 29.2%, and the negative predictive value 96.2%. The 1- and 2-year cumulative BM rates were (respectively) 10.8% and 27.4% in the high-risk group and 2.4 and 4.3% in the low-risk group. The hazard ratio for BM of the high- versus low-risk group was 9.240 (95% CI: 3.319–25.722).
Conclusion
The simple prediction model constructed from clinicopathological parameters is accurate in predicting BM development in HCC patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236
Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM (2006) New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 25(27):3848–3856
Feinstein AR (1972) Clinical biostatistics: XVI. The process of prognostic stratification. 2. Clin Pharmacol Ther 13(4):609–624
Fournier PG, Stresing V, Ebetino FH, Clézardin P (2010) How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia 12(7):571–578
Fukutomi M, Yokota M, Chuman H, Harada H, Zaitsu Y, Funakoshi A, Wakasugi H, Iguchi H (2001) Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 13(9):1083–1088
He J, Zeng ZC, Tang ZY, Fan J, Zhou J, Zeng MS, Wang JH, Sun J, Chen B, Yang P, Pan BS (2009) Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy. Cancer 115(12):2710–2720
Ho CL, Chen S, Cheng TK, Leung YL (2011) PET/CT characteristics of isolated bone metastases in hepatocellular carcinoma. Radiology 258(2):515–523
Horak CE, Steeg PS (2005) Metastasis gets site specific. Cancer Cell 8(2):93–95
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549
Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, Jeng YM, Liang JT, Lee PH, Chang KJ, Chau YP, Kuo ML (2005) Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 128(1):9–23
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108
Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655–1664
Shim H, Lau SK, Devi S, Yoon Y, Cho HT, Liang Z (2006) Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun 346(1):252–258
Tang ZY (2001) Hepatocellular carcinoma—cause, treatment and metastasis. World J Gastroenterol 7(4):445–454
Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K (2011) Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer Mar 22. doi:10.1002/cncr.25960
Ueno S, Tanabe G, Sako K, Hiwaki T, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T (2001) Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients: cancer of the liver Italian program. Hepatology 34(3):529–534
Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS (2010) Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 28(10):1660–1665
Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, Tan YS, He J (2009a) Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer 9:176
Xiang ZL, Zeng ZC, Tang ZY, Fan J, Sun H, Wu W, Tan Y (2009b) Increased expression of vascular endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is correlated with lymph node metastasis and poor outcome. Cancer J 15(6):519–525
Xiang ZL, Zeng ZC, Tang ZY, Fan J, He J, Zeng HY, Zhu XD (2011a) Potential prognostic biomarkers for bone metastasis from hepatocellular carcinoma. Oncologist 16(7):1028–1039
Xiang ZL, Zeng ZC, Tang ZY, Fan J, Sun HC, Tan YS (2011b) Expression of cytokeratin 19 and matrix metalloproteinase 2 predicts lymph node metastasis in hepatocellular carcinoma. Mol Biol Rep 38(5):3531–3539
Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY, Gao DM (2011c) Gene expression profiling of fixed tissues identified HIF-1{alpha}, VEGF, and MMP-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res 17(16):5463–5472
Yamazumi K, Nakayama T, Kusaba T, Wen CY, Yoshizaki A, Yakata Y, Nagayasu T, Sekine I (2006) Expression of interleukin-11 and interleukin-11 receptor alpha in human colorectal adenocarcinoma; immunohistochemical analyses and correlation with clinicopathological factors. World J Gastroenterol 12(2):317–321
Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC (2008) High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26(16):2707–2716
Acknowledgments
This work was supported by Grants No. 30973500 from the National Natural Science Foundation of China and the Youth Science Foundation of Zhongshan Hospital.
Conflict of interests
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xiang, ZL., Zeng, ZC., Fan, J. et al. A clinicopathological model to predict bone metastasis in hepatocellular carcinoma. J Cancer Res Clin Oncol 137, 1791–1797 (2011). https://doi.org/10.1007/s00432-011-1060-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-011-1060-7